PANTHERx® Rare Selected by Chiesi for the Distribution of MYCAPSSA®

PITTSBURGH, Oct. 13, 2025 /PRNewswire/ -- PANTHERx^® Rare has been chosen by Chiesi as the exclusive specialty pharmacy to distribute MYCAPSSA^® (octreotide). The partnership aims to improve patient access and support for individuals living with acromegaly.

MYCAPSSA^® is an oral somatostatin analog (SSA) indicated for the long-term maintenance treatment of acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.¹ SSAs work by decreasing growth hormone production associated with acromegaly.^1,2

Acromegaly is a rare condition that occurs from the overproduction of growth hormone by the pituitary gland, most commonly caused by a benign tumor on the gland called a pituitary adenoma. Symptoms of acromegaly can vary and include enlarged hands, feet, and facial features, thickened and oily skin, increased sweating, deeper voice, headaches, and joint aches.² Complications of acromegaly can include type 2 diabetes, high blood pressure, heart disease, sleep apnea, arthritis, and other conditions affecting the bones and muscles.² Treatment options may include surgery to remove the pituitary tumor, medications, and radiation therapy.²

"We are pleased to partner with Chiesi to distribute MYCAPSSA^® and support people living with acromegaly," said Bansi Nagji, CEO, PANTHERx Rare. "At PANTHERx, our mission is clear: to stand with individuals and families affected by rare diseases. Those in the acromegaly community often face access challenges and limited treatment options, and it is our responsibility—and our privilege—to provide the right treatment, tools, and personalized support they deserve."

About PANTHERx Rare
PANTHERx Rare is a specialty pharmacy exclusively focused on rare and orphan diseases, distributing several orphan products and providing access and support services to those needing them most. Known as The Rare Disease Pharmacy^®, PANTHERx transforms lives by delivering medicine breakthroughs, clinical excellence, and access solutions to people living with rare and devastating conditions.

PANTHERx is a dual-accredited specialty pharmacy, with notable distinctions in rare diseases, including the Accreditation Commission for Health Care (ACHC) Distinction in Orphan Drugs and Utilization Review Accreditation Commission (URAC) Rare Disease Center of Excellence. As a pharmacy focused on patient satisfaction, PANTHERx is the eight-time winner of the prestigious MMIT Patient Choice Award, including the 2025 honor. PANTHERx is headquartered in Pittsburgh, Pennsylvania and is licensed in all 50 states and U.S. territories.

For more information, please email [email protected] or visit www.pantherxrare.com.

About Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system.

IMPORTANT SAFETY INFORMATION

INDICATION AND USAGE: MYCAPSSA (octreotide) delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

CONTRAINDICATIONS: Hypersensitivity to octreotide or any of the components of MYCAPSSA. Anaphylactoid reactions, including anaphylactic shock, have been reported in patients receiving octreotide.

WARNINGS AND PRECAUTIONS: Can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected. Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly. Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted. New onset of steatorrhea, stool discoloration, loose stools, abdominal bloating, and weight loss may occur with MYCAPSSA and other somatostatin analogs. If new occurrence or worsening of these symptoms are reported, evaluate for potential pancreatic exocrine insufficiency and manage accordingly.

ADVERSE REACTIONS: The most common adverse reactions (incidence >10%) are nausea, diarrhea, headache, arthralgia, asthenia, hyperhidrosis, peripheral swelling, blood glucose increased, vomiting, abdominal discomfort, dyspepsia, sinusitis, and osteoarthritis.

For additional Important Safety Information, please see the MYCAPSSA^® full Prescribing Information at MYCAPSSA.com .

1. MYCAPSSA. Package Insert. Chiesi USA. 2024.
2. Acromegaly | NIDDK. National Institute of Diabetes and Digestive and Kidney Diseases. Accessed May 15, 2025. https://www.niddk.nih.gov/health-information/endocrine-diseases/acromegaly#who

©2025 Chiesi USA. MYCAPSSA^® is a registered trademark owned by the Chiesi Group.
Chiesi Total Care^SM is a service mark of CHIESI FARMACEUTICI S.p.A.
All rights reserved. PP-RA-01192 V1.0 09/2025

SOURCE PANTHERx Rare Pharmacy